U.S. flag

An official website of the United States government

NM_002691.4(POLD1):c.463+8_463+9delinsTT AND not provided

Germline classification:
Likely benign (1 submission)
Last evaluated:
Aug 26, 2016
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000590576.3

Allele description [Variation Report for NM_002691.4(POLD1):c.463+8_463+9delinsTT]

NM_002691.4(POLD1):c.463+8_463+9delinsTT

Gene:
POLD1:DNA polymerase delta 1, catalytic subunit [Gene - OMIM - HGNC]
Variant type:
Indel
Cytogenetic location:
19q13.33
Genomic location:
Preferred name:
NM_002691.4(POLD1):c.463+8_463+9delinsTT
HGVS:
  • NC_000019.10:g.50401932_50401933delinsTT
  • NG_033800.1:g.22610_22611delinsTT
  • NM_001256849.1:c.463+8_463+9delinsTT
  • NM_001308632.1:c.463+8_463+9delinsTT
  • NM_002691.4:c.463+8_463+9delinsTTMANE SELECT
  • LRG_785t1:c.463+8_463+9delinsTT
  • LRG_785t2:c.463+8_463+9delinsTT
  • LRG_785:g.22610_22611delinsTT
  • NC_000019.9:g.50905189_50905190delinsTT
  • NM_002691.2:c.463+8_463+9delinsTT
  • NM_002691.3:c.463+8_463+9delinsTT
Links:
dbSNP: rs796285537
NCBI 1000 Genomes Browser:
rs796285537
Molecular consequence:
  • NM_001256849.1:c.463+8_463+9delinsTT - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001308632.1:c.463+8_463+9delinsTT - intron variant - [Sequence Ontology: SO:0001627]
  • NM_002691.4:c.463+8_463+9delinsTT - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000698010Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely benign
(Aug 26, 2016)
germlineclinical testing

LabCorp Variant Classification Summary - May 2015.docx

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000698010.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Variant summary: The POLD1 c.463+8_463+9delinsTT variant involves the alteration of non-conserved nucleotides, resulting in a intronic change. This delins variant is not found in ExAC; however, the individual variants that form the variant of interest, viz. 19:50905189 G / T and 19:50905190 C / T are found at allele frequencies of 0.1145 (13864/ 121128) and 0.007434 (901/121202), respectively. In African sub-population, they have allele frequencies of 0.2939 and 0.08015, respectively. Therefore, it is highly likely they are in a considerable linkage disequilibrium such that the variant of interest also has a frequency that exceeds the estimated maximal expected allele frequency (0.00142) based on the disease prevalence of CRC. One clinical lab in ClinVar has classified it bas benign. The variant of interest has not been reported in affected individuals via publications, to our knowledge. Taken together, this variant is classified as likely benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024